Navigation Links
Eliminating rare diseases
Date:1/24/2013

al Rare Diseases Research Consortium (IRDiRC), under which these new grants have been awarded, aims to accelerate research into rare diseases. Professor Paul Lasko of McGill University in Montral, Canada, Chair-Elect of the IRDiRC Executive Committee, explained: "IRDiRC's goal is to reach 200 new rare disease therapies, and diagnoses for all rare diseases, by the year 2020. To this end, it is today launching three major projects which will combine international genetic data with clinical information and data on biomaterials to help interpret the vast amounts of data the genome yields. This will aid scientists in the search for genetic causes of diseases and help identify new ways to create targeted therapies".

Professor Lochmller said: "Already we have drugs being tested in clinical trials which can, in effect, patch up the faults in the genes for some rare diseases such as Duchenne muscular dystrophy. Drugs like this are at the vanguard of a new generation of therapies that change a person's genes rather than just treating their symptoms, and they have the potential to make a real difference to the quality of life of people with the condition. By sharing data and clinical expertise in this structured way across an international network, we hope to discover similar life-changing drugs for other rare diseases."

A rare disease is defined by the European Union as one that affects fewer than five people in every 10,000 of the general population. There are between 6,000 and 8,000 known rare diseases, and approximately 30 million people across Europe are affected by a rare disease.

The four IRDiRC projects being launched in Barcelona today have received nearly 40 million EUR of funding for cutting-edge research and collaboration over the next six years. Funding focuses on international collaborations:

  • Identifying the genetic and epigenetic causes of rare kidney disorders EURenOmics led by Heidelberg University Medical Centre, Germa
    '/>"/>

Contact: Karen Bidewell
press.office@ncl.ac.uk
44-019-122-27850
Newcastle University
Source:Eurekalert

Page: 1 2 3 4 5

Related biology news :

1. Eliminating useless information important to learning, making new memories
2. An error-eliminating fix overcomes big problem in 3rd-gen genome sequencing
3. Immune cell death defects linked to autoimmune diseases
4. Stem cell materials could boost research into key diseases
5. The findings between DNMs and autism provides global view of mutability on human diseases
6. Transplanted genetically-modified adipose cells offer potential therapy for liver diseases
7. Removing protein garbage in nerve cells may help control 2 neurodegenerative diseases
8. Short DNA strands in the genome may be key to understanding human cognition and diseases
9. Scientists question the designation of some emerging diseases
10. Call for global monitoring of infectious diseases in dogs and cats
11. Action needed to prevent more devastating tree diseases entering the UK
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ... robust – with the clinical data to back it ...
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ... "Global Facial Recognition Market 2015-2019" report to ... Facial recognition is a technology ... system measures the overall facial feature of a ... the distance between eyes. Facial recognition is used ...
(Date:12/11/2014)... Dec. 10, 2014  That blood pressure plays a role ... Hypertension – the medical term for high blood pressure – ... and the inflatable cuff that,s used in measuring blood pressure ... there,s nothing new about hypertension, its triggers and its effects. ... the condition and the best ways to treat it. ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... chloride ions are critical to hearing in mammals, which builds ... off boats might disrupt the balance of these ions in ... show that chloride ions are crucial for our exquisite sense ... Surgery and Neurobiology and first author of the study in ...
... and harvest gardens of fungus have a secret ... antibiotic-producing bacteria that the insects harbor on their ... an international team led by University of Wisconsin-Madison ... nature of this mutualistic relationship. The researchers ...
... beaches hit Rhode Island's Narragansett Bay during the summer ... which literally suffocates sea life. While some evidence of ... surface, Brown University ecologists went underwater and discovered a ... mussel reefs located in the central bay, researchers found ...
Cached Biology News:Study reveals classic symbiotic relationship between ants, bacteria 2Study reveals classic symbiotic relationship between ants, bacteria 3'Dead zone' summer killed billions of ocean state mussels 2
(Date:12/24/2014)... 2014 The report expects global cell ... 2019. It also provides a carefully analyzed data about ... for the market. , Full Copy of Report @ ... global market for cell expansion will keep witnessing growth ... this growth to be driven by rapid technological advancements, ...
(Date:12/24/2014)... , Dec. 23, 2014 Vermillion, Inc. ... on gynecologic disease, announced today that investors including ... Birchview Fund LLC and several Vermillion directors have ... shares of Vermillion,s common stock and warrants to ... a private placement.  Under the ...
(Date:12/24/2014)... Dec. 23, 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... filed a Clinical Trial Application (CTA) with the ... Agency (MHRA) seeking regulatory approval to initiate clinical trials ... Citrate. Contingent on the Company receiving CTA ... I trial to assess the safety, tolerability and dose ...
(Date:12/22/2014)... 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, ... today announced positive topline safety and tolerability ... of SYN-004, the Company,s investigational oral beta-lactamase ... difficile (C. difficile) infection, antibiotic-associated diarrhea ...
Breaking Biology Technology:The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... Leaders of Milwaukee, Racine, and Waukesha counties signed an ... expansion of the Center for Advanced Technology and ... is intended to increase the number of high-paying technology ... in order to keep area innovations in technology from ...
... Morgan Stanley in the Ronald Perelman case is a clarion ... First, a quick recap of the main points in the ... sued by billionaire financier Ronald Perelman , Morgan Stanley could ... in the case ruled that Morgan Stanley deliberately violated her ...
... Madison, Wis. - Governor Jim Doyle announced Friday ... Wisconsin. , ,The Consortium on Biobased Industry, ... private sectors, will work with the State Departments of ... Office to determine what the state government can do ...
Cached Biology Technology:Southeastern Wisconsin Technology Collaboration 2Southeastern Wisconsin Technology Collaboration 3Southeastern Wisconsin Technology Collaboration 4$1.45 billion judgment against Morgan Stanley sends message revisit e-mail retention policies 2$1.45 billion judgment against Morgan Stanley sends message revisit e-mail retention policies 3Doyle announces biobased energy consortium 2Doyle announces biobased energy consortium 3
...
... polyclonal to MSY2/YBOX2 ( Abpromise ... Antigen: Synthetic peptide derived ... 178-227 of human YBX2. (Note: ... proprietary). ...
... Freedom EVO96R and Freedom EVO384R are fast ... available in three different sizes, with a ... They deliver significant time saving, with true ... easy setup of your assays with the ...
... General description: Aminopropylsilane is ... used slide chemistry for ... Coated Slides for Microarrays ... glass substrate for printing ...
Biology Products: